144 related articles for article (PubMed ID: 32868349)
1. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.
Khunti K; Gomes MB; Kosiborod M; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Tang F; Ji L;
BMJ Open; 2020 Aug; 10(8):e034613. PubMed ID: 32868349
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Nicolucci A; Charbonnel B; Gomes MB; Khunti K; Kosiborod M; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Pocock S
Diabetes Obes Metab; 2019 Nov; 21(11):2474-2485. PubMed ID: 31297947
[TBL] [Abstract][Full Text] [Related]
3. Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study.
van Dalem J; Brouwers MCGJ; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Driessen JHM
Diabetes Res Clin Pract; 2021 Jun; 176():108828. PubMed ID: 33894280
[TBL] [Abstract][Full Text] [Related]
4. Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
Gomes MB; Rathmann W; Charbonnel B; Khunti K; Kosiborod M; Nicolucci A; Pocock SJ; Shestakova MV; Shimomura I; Tang F; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Ji L;
Diabetes Res Clin Pract; 2019 May; 151():20-32. PubMed ID: 30904743
[TBL] [Abstract][Full Text] [Related]
5. Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines.
Wang TY; Eguale T; Tamblyn R
BMC Health Serv Res; 2013 Oct; 13():442. PubMed ID: 24160916
[TBL] [Abstract][Full Text] [Related]
6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
7. Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.
Geier AS; Wellmann I; Wellmann J; Kajüter H; Heidinger O; Hempel G; Hense HW
Diabetes Res Clin Pract; 2014 Oct; 106(1):73-80. PubMed ID: 25139631
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?
Wood SJ; Magliano DJ; Bell JS; Shaw JE; Keen CS; Ilomäki J
Diabet Med; 2020 Aug; 37(8):1367-1373. PubMed ID: 31557346
[TBL] [Abstract][Full Text] [Related]
9. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.
Morgan CL; Poole CD; Evans M; Barnett AH; Jenkins-Jones S; Currie CJ
J Clin Endocrinol Metab; 2012 Dec; 97(12):4605-12. PubMed ID: 23076348
[TBL] [Abstract][Full Text] [Related]
10. Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis.
Burgmann K; Fatio S; Jordi B; Rutishauser J
Swiss Med Wkly; 2013; 143():w13871. PubMed ID: 24163110
[TBL] [Abstract][Full Text] [Related]
11. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
12. Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Khunti K; Chen H; Cid-Ruzafa J; Fenici P; Gomes MB; Hammar N; Ji L; Kosiborod M; Pocock S; Shestakova MV; Shimomura I; Tang F; Watada H; Nicolucci A;
Diabetes Obes Metab; 2020 Jan; 22(1):66-78. PubMed ID: 31468637
[TBL] [Abstract][Full Text] [Related]
13. Patterns of metformin monotherapy discontinuation and reinitiation in people with type 2 diabetes mellitus in New Zealand.
Horsburgh S; Sharples K; Barson D; Zeng J; Parkin L
PLoS One; 2021; 16(4):e0250289. PubMed ID: 33882106
[TBL] [Abstract][Full Text] [Related]
14. Management and treatment goals in Polish patients with type 2 diabetes of short duration: results of the ARETAEUS2-Grupa study.
Bała MM; Płaczkiewicz-Jankowska E; Leśniak W; Topór-Mądry R; Michałejko M; Jankowski M; Strzeszyński L; Sieradzki J; Czupryniak L;
Pol Arch Med Wewn; 2013; 123(11):573-81. PubMed ID: 24241157
[TBL] [Abstract][Full Text] [Related]
15. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
16. Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.
Ji L; Bonnet F; Charbonnel B; Gomes MB; Kosiborod M; Khunti K; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Fenici P; Hammar N; Hashigami K; Macaraeg G; Surmont F; Medina J
J Diabetes Complications; 2017 Jul; 31(7):1188-1196. PubMed ID: 28499961
[TBL] [Abstract][Full Text] [Related]
17. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).
Kosiborod M; Gomes MB; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Watada H; Shimomura I; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Khunti K;
Cardiovasc Diabetol; 2018 Nov; 17(1):150. PubMed ID: 30486889
[TBL] [Abstract][Full Text] [Related]
18. Prescribing practices and clinical predictors of glucose-lowering therapy within the first year in people with newly diagnosed Type 2 diabetes.
Mor A; Berencsi K; Svensson E; Rungby J; Nielsen JS; Friborg S; Brandslund I; Christiansen JS; Vaag A; Beck-Nielsen H; Sørensen HT; Thomsen RW
Diabet Med; 2015 Dec; 32(12):1546-54. PubMed ID: 26032247
[TBL] [Abstract][Full Text] [Related]
19. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
Lu CH; Yang CY; Li CY; Hsieh CY; Ou HT
Diabetologia; 2018 Mar; 61(3):562-573. PubMed ID: 29138876
[TBL] [Abstract][Full Text] [Related]
20. Treatment pathways in people with type 2 diabetes mellitus: a nationwide cohort study of new users of metformin monotherapy in New Zealand.
Guo J; Parkin L; Zeng J; Barson D; Horsburgh S
BMJ Open; 2021 Aug; 11(8):e051884. PubMed ID: 34408057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
